Nutrition & Diet
Zeaxanthin From Leafy Greens May Supercharge Cancer Immunotherapy
Common eye-health nutrient zeaxanthin strengthens immune T cells and enhances cancer treatment effectiveness in new research.
Press Release
Apr 11, 2026 0
Results for "Astaxanthin"
20 articles
Longevity & Aging
Novel Pancreatic Cancer Drug Daraxonrasib Shows Unprecedented Survival Gains in Early Data
Daraxonrasib targets RAS mutations in pancreatic cancer, showing 35% response rates and 13-month survival — far outpacing current chemo options.
Press Release
May 7, 2026 0
Longevity & Aging
Sustained-Release Eye Implant Outperforms Standard Injections for Wet AMD
A VEGF inhibitor implant preserved vision in 74% of wet AMD patients at 36 weeks, beating standard aflibercept therapy in a phase III trial.
Press Release
May 7, 2026 0
Longevity & Aging
New RAS Inhibitor Doubles Survival in Pancreatic Cancer Plus Gut Microbiome Predicts Melanoma Recurrence
A phase III trial shows daraxonrasib doubled median survival in advanced pancreatic cancer, while gut bacteria may predict melanoma relapse risk.
Press Release
Apr 18, 2026 0
Longevity & Aging
Pancreatic Cancer Drug Daraxonrasib Nearly Doubles Survival But Access Remains Scarce
Revolution Medicines' daraxonrasib nearly doubled survival in pancreatic cancer trials, but surging demand is leaving patients anxious about access.
Press Release
Jun 5, 2026 0
Longevity & Aging
FDA Approves First Aldosterone Synthase Inhibitor BAXFENDY to Tackle Resistant Hypertension
AstraZeneca's BAXFENDY cuts systolic blood pressure by nearly 10 mmHg beyond placebo in adults whose BP wasn't controlled by other drugs.
Press Release
May 20, 2026 0
Longevity & Aging
Novel Oral Drug Doubles Survival in Pancreatic Cancer Patients
A phase III trial shows daraxonrasib doubled overall survival vs chemotherapy in metastatic pancreatic cancer, signaling a new standard of care.
Press Release
Jun 1, 2026 0
Longevity & Aging
Drug ATX-304 Activates AMPK Pathway and Boosts Metabolism in First Human Trial
Cambrian Bio's ATX-304 reduced liver fat, visceral fat, and raised resting metabolic rate by 8% in a Phase 1b trial of adults with prediabetes.
Press Release
Jun 20, 2026 0
Longevity & Aging
Engineered Macrophage Therapy Shows Promise Against Liver Fibrosis in Preclinical Study
RTX001, a regenerative macrophage cell therapy, reduced liver inflammation and fibrosis in mouse models ahead of Phase I/II trial results.
Press Release
May 16, 2026 0
Longevity & Aging
New Oral Drug ATX-304 Targets Obesity and Prediabetes by Activating Cellular Energy Sensors
Cambrian Bio's ATX-304 combines AMPK and mitochondrial activation in a pill form, with Phase 1b data in prediabetic obese adults due this week.
Press Release
Jun 5, 2026 0
Longevity & Aging
New Drug Doubles Survival Time for Pancreatic Cancer Patients in Major Trial
Daraxonrasib nearly doubled median survival in pancreatic cancer patients, offering real hope for one of oncology's deadliest diagnoses.
Press Release
Jun 20, 2026 0
Longevity & Aging
Gene Therapy PST-611 Shows Early Promise Against Dry AMD in Phase 1 Trial
PulseSight's iron-regulating gene therapy slowed geographic atrophy growth in a first-in-human trial, with Phase 2 planned for 2026.
Press Release
May 13, 2026 0
Longevity & Aging
FDA Fast-Tracks Expanded Access for Promising Pancreatic Cancer Drug Daraxonrasib
The FDA approved expanded access in just 2 days for daraxonrasib, a RAS inhibitor targeting the most common pancreatic cancer mutation.
Press Release
May 2, 2026 0
Regenerative Medicine
Astellas Stem Cell Eye Therapy Shows Early Promise for Age-Related Vision Loss
Astellas reports encouraging early-stage results for a stem cell-derived treatment targeting age-related eye disease, though data remains limited.
Press Release
May 11, 2026 0
Longevity & Aging
Experimental Drug Doubles Survival Time in Pancreatic Cancer Patients
Revolution Medicines begins shipping daraxonrasib under FDA early access after Phase 3 trial showed nearly 2x survival vs chemotherapy.
Press Release
May 31, 2026 0
Regenerative Medicine
FDA Approves Baxdrostat as New Option for Hard-to-Treat High Blood Pressure
AstraZeneca's baxdrostat wins FDA approval for hypertension, offering a novel mechanism for patients uncontrolled on existing therapies.
Press Release
May 19, 2026 0
Longevity & Aging
New Pill Doubles Survival in Pancreatic Cancer Patients in Landmark Trial
Daraxonrasib nearly doubled survival vs. standard chemo in a major ASCO trial — a potential turning point for one of cancer's deadliest diagnoses.
Press Release
Jun 1, 2026 0
Longevity & Aging
New AMPK Drug Boosts Metabolism and Cuts Liver Fat in Prediabetes Trial
ATX-304 raised resting metabolic rate 8%, slashed triglycerides, and reduced liver fat in an 8-week Phase 1b trial for prediabetes.
Press Release
Jun 20, 2026 0
Longevity & Aging
New Heart Failure Drug TX45 Completes Phase 2 Enrollment Across 14 Countries
Tectonic Therapeutic enrolls 191 patients in a global trial of TX45, a novel fusion protein targeting a deadly heart-lung condition.
Press Release
Jun 13, 2026 0
Longevity & Aging
New Pill Doubles Survival Time for Advanced Pancreatic Cancer Patients
Daraxonrasib extended median survival to 13.2 months vs 6.7 months on chemo in a Phase 3 trial — a potential landmark for one of cancer's deadliest diagnoses.
Press Release
Apr 18, 2026 0
Page 1 of 2Next